Archive for the ‘Cholesterol drugs’ Category
Posted in Cholesterol drugs, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, tagged Baltimore, cancer research, catheter, Cholesterol levels, cholesterol-lowering, Johns Hopkins, prostate, prostate blog, PROSTATE CANCER, prostate-specific antigen, risk of high-grade prostate cancer, statins are protective on November 4, 2009 | Leave a Comment »
URO TODAY: Cholesterol levels and prostate cancer definitely seem to be connected, a new study at Johns Hopkins in Baltimore has revealed. READ MORE>
Our study supports two prior ones suggesting that cholesterol influences risk of high-grade prostate cancer, and indirectly supports the hypothesis that cholesterol-lowering is a mechanism by which statins are protective.
Posted in Cholesterol drugs, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged arthritis pain drug, cancer research, cancer-killing drugs, Celebrex and Lipitor, celecoxib and atrovastatin, cholesterol-lowering drugs, nuclear factor kappa B (NFkB), prostablog, prostate, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on April 29, 2009 | Leave a Comment »
AMERICAN JOURNAL OF HEMATOLOGY/ONCOLOGY: Can combination therapy with Celebrex and Lipitor effectively treat patients with early-stage prostate cancer? A new study at The Cancer Institute of New Jersey (CINJ) will explore that question.
Recent studies have shown that celecoxib and atrovastatin individually have effects on blocking nuclear factor kappa B (NFkB), the protein complex that, in many cases, can cause tumor cells to grow. By combining the two drugs, researchers will attempt to prevent tumor cells from growing and make them more sensitive to cancer-killing drugs. READ MORE>
Posted in Avoidance, Cholesterol drugs, PROSTATE CANCER, PROSTATE RESEARCH, tagged American Urological Association, cancer research, cholesterol, cholesterol-lowering drugs, Mayo Clinic, prostablog, prostate, PROSTATE CANCER, statins on April 27, 2009 | Leave a Comment »
REUTERS: Cholesterol-lowering statin drugs may protect men against prostate cancer and other urological complaints.
A clinical study following 2447 men over 15 years found those taking statins were less likely to develop prostate cancer. Just 6% of men on statins were diagnosed with prostate cancer, with non-statin users three times more likely to develop the disease, Mayo Clinic researchers have reported at the American Urological Association meeting in Chicago. READ MORE>